Skip to main content
SpringerLink
Log in

Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

This study describes the inhibitory effect of 5α-dihydrotestosterone (5α-DHT) and its precursors testosterone (T) and androst-4-ene-3,17-dione (Δ4-DIONE) on the growth of the estrogen-sensitive human breast cancer cell line ZR-75-1. In the absence of estrogens, cell proliferation measured after a 12-day incubation period was 50–60% inhibited by maximal concentrations of 5α-DHT, T, or Δ4-DIONE with half-maximal effects (IC50 values) observed at 0.10, 0.15 and 15 nM, respectively. This growth inhibition by androgens was due to an increase in generation time and a lowering of the saturation density of cell cultures. The antiestrogen LY156758 (300 nM) induced 25–30% inhibition of basal cell growth, its effect being additive to that of 5α-DHT. The mitogenic effect of 1 nM estradiol (E2) was completely inhibited by increasing concentrations of 5α-DHT with a potency (IC50 = 0.10 nM) similar to that measured when the androgen was used alone. E2 had a more repid effect on cell proliferation than 5α-DHT, the latter requiring at least 5 to 6 days to exert significant growth inhibition. As found in the absence of estrogens, maximal inhibition of cell proliferation in the presence of E2 was achieved by the combination of the antiestrogen and 5α-DHT. Supraphysiological concentrations of E2 (up to 1µM) were needed to completely reverse the growth inhibitory effect of a submaximal concentration of 5α-DHT (1 nM). The antiproliferative effect of androgens was competitively reversed by the antiandrogen hydroxyflutamide, thus indicating an androgen receptor-mediated mechanism. The present data suggest the potential benefits of an androgen-antiestrogen combination therapy in the endocrine management of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fels E: Treatment of breast cancer with testosterone propionate. A preliminary report. J Clin Endocrinol 4: 121–125, 1944

    Google Scholar 

  2. Segaloff A, Gordon D, Horwitt BN, Schlosser JV, Murison PJ: Hormonal therapy in cancer of the breast. 1. The effect of testosterone propionate therapy on clinical course and hormonal excretion. Cancer 4: 319–323, 1951

    PubMed  Google Scholar 

  3. Cooperative Breast Cancer Group: Testosterone propionate therapy of breast cancer. J Amer Med Assoc 188: 1069–1072, 1964

    Google Scholar 

  4. Kennedy BJ: Fluoxymesterone therapy in treatment of advanced breast cancer. N Engl J Med 259: 673–675, 1958

    PubMed  Google Scholar 

  5. Tormey DC, Lippman ME, Cassidy JG: Evaluation of Tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98: 139–143, 1983

    PubMed  Google Scholar 

  6. Gordan GS, Halden A, Horn Y, Fuery JJ, Parsons RJ, Walter RM: Calusterone (7β,17α-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer. Oncology 28: 138–146, 1973

    PubMed  Google Scholar 

  7. Gordan GS: In: Kochakian CD (ed) Anabolic-androgenic steroids. Handbook of Experimental Pharmacology, vol 43. Springer-Verlag, New York, 1976, pp 499–513

    Google Scholar 

  8. Segaloff A: The use of androgens in the treatment of neoplastic disease. Pharmac Ther C2: 33–37, 1977

    Google Scholar 

  9. McGuire WL, Carbone PP, Sears ME, Escher GC: Estrogen receptors in human breast cancer: an overview. In: McGuire WL, Carbone PP, Vollmer EP (eds) Estrogen Receptors in Breast Cancer, Raven Press, New York, 1975, pp 1–7

    Google Scholar 

  10. Wittliff JL: Steroid binding proteins in normal and neoplastic mammary cells. In: Busch H (ed) Methods in Cancer Research, vol 11 Academic Press, New York, 1975, pp 298–304

    Google Scholar 

  11. Allegra JC, Lippman ME, Thompson EG, Simon R, Barlock A, Green L, Huff KK, Do HMT, Aitken SC: Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 39: 1447–1454, 1979

    PubMed  Google Scholar 

  12. Horwitz KB, Zava DT, Thilager AK, Jensen ET, McGuire WL: Steroid receptor analyses of nine human breast cancer cell lines. Cancer Res 38: 2434–2439, 1978

    PubMed  Google Scholar 

  13. Lippman M, Bolan G, Huff K: The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4610–4618, 1976

    PubMed  Google Scholar 

  14. Westley B, Rochefort H: A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20: 353–362, 1980

    PubMed  Google Scholar 

  15. Zava DT, McGuire WL: Human breast cancer: androgen action mediated by estrogen receptor. Science 199: 787–788, 1978

    PubMed  Google Scholar 

  16. Zava DT, McGuire WL: Androgen action through estrogen receptor in a human breast cancer cell line. Endocrinology 103: 624–631, 1978

    PubMed  Google Scholar 

  17. McIndoe JH, Etre LA: An antiestrogenic action of androgens in human breast cancer cells. J Clin Endocrinol Metab 53: 836–842, 1981

    PubMed  Google Scholar 

  18. Shapiro E, Lippman ME: Onset of androgen action in MCF-7 human breast cancer cells is not accompanied by receptor depletion. J Steroid Biochem 22: 15–20, 1985

    PubMed  Google Scholar 

  19. Chalbos D, Haagensen D, Parish T, Rochefort H: Identification and androgen regulation of two proteins released by T47D human breast cancer cells. Cancer Res 47: 2787–2792, 1987

    PubMed  Google Scholar 

  20. Murphy LC, Tsuyuki D, Myal Y, Shiu RPC: Isolation and sequencing of a cDNA clone for a prolactin-inducible protein (PIP). J Biol Chem 262: 15236–15241, 1987

    PubMed  Google Scholar 

  21. Simon WE, Palinke VG, Hölzel F:In vitro modulation of prolactin binding to human mammary carcinoma cells by steroid hormones and prolactin. J Clin Endocrinol Metab 60: 1243–1249, 1985

    PubMed  Google Scholar 

  22. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ: Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 38: 3352–3364, 1978

    PubMed  Google Scholar 

  23. Neri R, Peets E, Watnick A: Antiandrogenicity of flutamide and its metabolite Sch16423. Biochem Soc Trans 7: 565–569, 1979

    PubMed  Google Scholar 

  24. Simard J, Luthy I, Guay J, Bélanger A, Labrie F: Characteristics of interaction of the antiandrogen Flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 44: 261–270, 1986

    PubMed  Google Scholar 

  25. Clemens JA, Bennett DR, Black LJ, Jones CD: Effects of a new antiestrogen, keoxifene (LY156758), on growth of car-cinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 32: 2869–2875, 1983

    PubMed  Google Scholar 

  26. Simard J, Labrie F: Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs. Mol Cell Endocrinol 39: 141–144, 1985

    PubMed  Google Scholar 

  27. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83: 2496–2500, 1986

    PubMed  Google Scholar 

  28. Hubert JF, Vincent A, Labrie F: Estrogenic activity of phenol red in rat anterior pituitary cells in culture. Biochem Biophys Res Commun 141: 885–891, 1986

    PubMed  Google Scholar 

  29. Poulin R, Labrie F: Stimulation of cell proliferation and estrogenic response by adrenal C19-Δ5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46: 4933–4937, 1986

    PubMed  Google Scholar 

  30. Taylor CM, Blanchard B, Zava DT: A simple method to determine whole cell uptake of radiolabeled oestrogens and progesterone and their subcellular localization in breast cancer cell lines in monolayer cultures. J Steroid Biochem 20: 1083–1088, 1984

    PubMed  Google Scholar 

  31. Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672, 1959

    Google Scholar 

  32. Rodbard D: Apparent positive cooperative effect in cyclic AMP and corticosterone production by related adrenal cells in response to ACTH analogs. Endocrinology 94: 1427–1437, 1974

    PubMed  Google Scholar 

  33. Cheng Y, Prusoff WH: Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108, 1973

    PubMed  Google Scholar 

  34. Kramer CY: Extension of multiple-range test to group means with unique numbers of replications. Biometrics 12: 307–310, 1956

    Google Scholar 

  35. Rochefort H, Garcia M: The estrogenic and antiestrogenic activities of androgens in female target tissues. Pharmac Ther 23: 193–216, 1983

    Google Scholar 

  36. Garcia M, Rochefort H: Androgen on the oestrogen receptor: II. Correlation between nuclear translocation and uterine protein synthesis. Steroids 29: 111–126, 1977

    PubMed  Google Scholar 

  37. Huggins C, Jensen EV, Cleveland AS: Chemical structure of steroids in relation to promotion of growth of the vagina and uterus of the hypophysectomized rat. J Exp Med 100: 225–240, 1954

    PubMed  Google Scholar 

  38. Hilf R: Anabolic-androgenic steroids and experimental mammary tumors. In: Kochakian CD (ed) Anabolic-androgenic steroids. Handbook of Experimental Pharmacology, vol 43, pp 191–210, 1976

    Google Scholar 

  39. Garcia M, Rochefort H: Androgen effects mediated by estrogen receptor in 7,12-dimethylbenz(a)anthracene-in-duced rat mammary tumors. Cancer Res 38: 3922–3929, 1978

    PubMed  Google Scholar 

  40. Lippman M, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595–4601, 1976

    PubMed  Google Scholar 

  41. Reiner GCA, Katzenellenbogen BS, Bindal RD, Katzenellenbogen JA: Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells. Cancer Res 44: 2302–2308, 1984

    PubMed  Google Scholar 

  42. Raynaud JP, Ojasoo T: Receptor binding as a tool in the development of selective new bioactive steroids and nonsteroids.In: Harms AF (ed) Innovative Approaches in Drug Research. Elsevier, Amsterdam, 1986, pp 47–72

    Google Scholar 

  43. Abraham GE: Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 39: 340–346, 1974

    PubMed  Google Scholar 

  44. Vermeulen A, Verdonck L: Factors affecting sex hormone levels in postmenopausal women. J Steroid Biochem 11: 899–904, 1979

    PubMed  Google Scholar 

  45. Mistry P, Griffiths K, Maynard PV: Endogenous C19-steroids and estradiol levels in human primary breast tumor tissues and their correlation with androgen and estrogen receptors. J Steroid Biochem 24: 1117–1125, 1986

    PubMed  Google Scholar 

  46. McIndoe JH, Woods GR, Lee FJ: The specific binding of androgens and the subsequent distribution of androgen receptor complexes within MCF-7 human breast cancer cells. Steroids 38: 439–452, 1981

    PubMed  Google Scholar 

  47. Perel E, Daniilescu D, Kharlip L, Blackstein ME, Killinger DW: The relationship between growth and androstenedione metabolism in four cell lines of human breast carcinoma cells in culture. Mol Cell Endocrinol 41: 197–203, 1985

    PubMed  Google Scholar 

  48. Griffiths K, Jones D, Cameron EHD, Gleave EN, Forrest APM: Transformation of steroids by mammary cancer tissue.In: Dao TL (ed) Oestrogen Target Tissues and Neoplasia. University of Chicago Press, Chicago, 1972, pp 125–136

    Google Scholar 

  49. Perel E, Killinger DW: The metabolism of androstenedione and testosterone to C19-metabolites in normal breast, breast carcinoma, and benign prostatic hypertrophy tissue. J Steroid Biochem 19: 1135–1139, 1983

    PubMed  Google Scholar 

  50. Ip M, Milholland RJ, Kim U, Rosen F: Androgen control of cytosol progesterone receptor levels in the MT-W9B transplantable mammary tumor in the rat. J Natl Cancer Inst 69: 673–691, 1982

    PubMed  Google Scholar 

  51. Jellinek PH, Newcombe AM: Androgen receptor-mediated inhibition of estrogen-induced uterine peroxidase. J Steroid Biochem 19: 1713–1717, 1983

    PubMed  Google Scholar 

  52. Li SA, Li JJ: Estrogen-induced progesterone receptor in the Syrian hamster kidney. I. Modulation by antiestrogens and androgens. Endocrinology 103: 2119–2128, 1978

    PubMed  Google Scholar 

  53. Tam S-P, Archer TK, Deeley RG: Biphasic effects of estrogen on apolipoprotein synthesis in human hepatoma cells. Mechanism of antagonism by testosterone. Proc Natl Acad Sci USA 83: 3111–3115, 1986

    PubMed  Google Scholar 

  54. Stover EP, Krishman AV, Feldman D: Estrogen downregulation of androgen receptors in cultured human mammary cancer cells (MCF-7). Endocrinology 120: 2597–2603, 1987

    PubMed  Google Scholar 

  55. Taylor CM, Blanchard B, Zava DT: Estrogen-receptor mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res 44: 1409–1414, 1984

    PubMed  Google Scholar 

  56. Bardon S, Vignon F, Montcourrier P, Rochefort H: Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 47: 1441–1448, 1987

    PubMed  Google Scholar 

  57. Strobl JS, Lippman ME: Prolonged retention of estradiol by human breast cancer cells in tissue culture. Cancer Res 39: 3319–3327, 1979

    PubMed  Google Scholar 

  58. Huggins C, Briziarelli G, Sutton H Jr: Rapid induction of mammary carcinoma in the rat and the influence of hormone on the tumors. J Exp Med 109: 25–42, 1959

    PubMed  Google Scholar 

  59. Heise E, Gorlich M: Growth and therapy of mammary tumors induced by 7,12-dimethylbenz(a)anthracene in rats. Br J Cancer 20: 539–545, 1966

    PubMed  Google Scholar 

  60. Horwitz HB: The structure and function of progesterone receptors in breast cancer. J Steroid Biochem 27: 447–457, 1987

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MRC Group in Molecular Endocrinology, Laval University Medical Center, G1V 4G2, Quebec, Canada

    Richard Poulin, Denis Baker & Fernand Labrie

Authors
  1. Richard Poulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Denis Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fernand Labrie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poulin, R., Baker, D. & Labrie, F. Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Tr 12, 213–225 (1988). https://doi.org/10.1007/BF01805942

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01805942

Key words

Search

Navigation